Emily Townsend

Emily is an associate in Goodwin’s Technology and Life Sciences group in London. Emily advises clients on a broad range of corporate matters, with a particular focus on transactions in the technology sector. Emily has experience advising on venture capital and growth equity transactions, mergers and acquisitions and general corporate matters. 

Prior to joining Goodwin, Emily was an associate in the Corporate Technology team at Taylor Wessing LLP.

• Myricx on its £90 million Series A financing, co-led by Novo Holdings and Abingworth
• Anaphite on its £10.4 million funding round
• ETF Partners on its investment in the $75 million Series C financing of Riverlane
• Oxford Quantum Circuits on its US$100 million series B financing
• Relay Technologies on its US$10 million seed financing
• Agfunder on its investment into Nium as part of a US$3m seed financing 
• VavaCars on its US$37m series C financing*
• Geopura on its GBP£36 million series A financing*
• Dawn Capital on its investment into Elwood Technologies as part of a US$70 million series A financing*
• Current Health on an acquisition by Best Buy for $400 million*
• Trustology on its sale to Bitpanda*

*Denotes experience prior to joining Goodwin